Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Reaxense aids in their synthesis and provision.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


We employ our advanced, specialised process to create targeted libraries for receptors.


 

Fig. 1. The screening workflow of Receptor.AI

This process includes extensive molecular simulations of the receptor in its native membrane environment, along with ensemble virtual screening that accounts for its conformational mobility. In the case of dimeric or oligomeric receptors, the entire functional complex is modelled, identifying potential binding pockets on and between the subunits to encompass all possible mechanisms of action.


Our library distinguishes itself through several key aspects:


  • The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.

  • The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.

  • The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.

  • In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
P35372

UPID:
OPRM_HUMAN

ALTERNATIVE NAMES:
Mu opiate receptor; Mu opioid receptor

ALTERNATIVE UPACC:
P35372; B0FXJ1; B2R9S7; B8Q1L7; B8Q1L8; B8Q1L9; E7EWZ3; G8XRH6; G8XRH8; Q12930; Q4VWM1; Q4VWM2; Q4VWM3; Q4VWM4; Q4VWM6; Q4VWX6; Q5TDA1; Q6UPP1; Q6UQ80; Q7Z2D8; Q86V80; Q8IWW3; Q8IWW4; Q9UCZ4; Q9UN57

BACKGROUND:
The Mu opioid receptor, alternatively known as the Mu opiate receptor, is integral to the opioid system's function, binding various ligands to modulate pain, reward, and addictive behaviors. Its activation by endogenous opioids and synthetic analogs initiates signaling through G-protein coupled pathways, influencing neurotransmitter release and cellular excitability. The receptor's ability to couple with different G-proteins allows for diverse physiological effects, from pain relief to mood alterations.

THERAPEUTIC SIGNIFICANCE:
Exploring the Mu opioid receptor's function illuminates pathways for novel drug development, targeting pain management and addiction treatment. By harnessing its receptor dynamics and signaling specificity, researchers can design targeted therapies that minimize adverse effects while maximizing therapeutic benefits, offering hope for patients with chronic pain and opioid use disorders.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.